العلاقة التعبيرية بين P52 و BCL2 في النساء العراقيات المصابات بسرطان الثدي

Al-Haddad R, Jasim, MH, Saleh,WA. Lack of Association between LCS6 Variant in KRAS Gene with the Occurrence of Breast Tumors in Iraqi Women. Baghdad Sci J. 2020 May 10; 17(2): 0426-0430.

AL-Thaweni AN, Yousif WH, Hassan SS. Detection of BRCA1and BRCA2 mutation for Breast Cancer in Sample of Iraqi Women above 40 Years. Baghdad Sci J. 2010;7(1): 1-7. ‎

Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014 Aug 10; 5(3): 283.

Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci. 2017 Apr 1;3(1):5-11.

Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol.Hum Reprod. 1998 Dec 1; 4(12): 1099-109.

Bouchalova K, Kharaishvili G, Bouchal J, Vrbkova J, Megova M, Hlobilkova A. Triple negative breast cancer-BCL2 in prognosis and prediction. Review. Curr Drug Targets. 2014 Nov 1; 15(12): 1166-75.

Leung LK, Wang TT. Paradoxical regulation of Bcl-2 family proteins by 17β-oestradiol in human breast cancer cells MCF-7. Br J Cancer. 1999 Oct; 81(3): 387-92.

Choi JE, Kang SH, Lee SJ, Bae YK. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy. Tumor Biol. 2014 Dec; 35(12): 12255-63.

Samy N, Ragab HM, El Maksoud NA, Shaalan M. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark. 2010 Jan 1; 6(2): 63-72.

Kim HS, Moon HG, Han W, Yom CK, Kim WH, Kim JH, Noh DY. COX2 overexpression is a prognostic marker for Stage III breast cancer. Breast Cancer Res Treat. 2012 Feb; 132(1): 51-9.

Tsutsui S, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, et al. Bcl-2 protein expression is associated with p27 and p53 protein expres¬sions and MIB-1 counts in breast cancer. BMC Cancer 2006; 6: 187.

Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res. 1995 Feb 1;1(2):189-98.

Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol. 2013 Nov 1; 24(11): 2801-7.

Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, et al. Prognostic influence of BCL2 expression in breast cancer. Int J Cancer. 2012 Oct 1; 131(7): E1109-19.

Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non–“triple-negative” tumors. Hum Pathol. 2012 Jan 1; 43(1): 23-30.

Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998 Apr; 16(1): 225-60.

Ling J, Kumar R. Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett. 2012 Sep 28; 322(2): 119-26.

Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. J Immunol 2006 Dec 1; 177(11): 7485-96.

Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010 Sep; 29(3): 405-34.

Gilmore T D. Multiple myeloma: lusting for NF-kappaB. Cancer cell 2007, 12 (2): 95–97.

Greten FR, Karin M. The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer. Cancer Lett. 2004 Apr 8; 206(2): 193-9.

Dimitrakopoulos FI, Antonacopoulou AG, Kottorou A, Vlotinou H, Panagopoulos ND, Dougenis D, et al. NSCLC and the alternative pathway of NF-κB: uncovering an unknown relation. Virchows Arch. 2012 May; 460(5): 515-23.

Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene. 2000 Feb; 19(9): 1123-31.

Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005 Oct; 93(9): 1019-23.

Seo SI, Song SY, Kang MR, Kim MS, Oh JE, Kim YR, et al. Immunohistochemically analysis of NF‐κB signaling proteins IKKε, p50/p105, p52/p100 and RelA in prostate cancers. Acta Pathol Microbiol Scand. 2009 Aug; 117(8): 623-8.

Wharry CE, Haines KM, Carroll RG, May MJ. Constitutive noncanonical NFκB signaling in pancreatic cancer cells. Cancer Biol Ther. 2009 Aug 15; 8(16): 1567-76.

Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi JJ, Matei D. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer. Neoplasia. 2013 Jun 1; 15(6): 609-IN8.

Uno M, Saitoh Y, Mochida K, Tsuruyama E, Kiyono T, Imoto I, et al. NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression. PLoS One. 2014; 9(2): e88347.

Saxon J A, Yu H, Polosukhin V V, Stathopoulos G T, Gleaves LA, McLoed A G, et al. p52 expression enhances lung cancer progression. Sci Rep. 2018; 8(1): 6078.

Čečka F, Hornychová H, Melichar B, Ryška A, Jandík P, Mergancová J. and Klozová-Urminská H. Expression of Bcl-2 In Breast Cancer: Correlation with Clinicopathological Characteristics and Survival. Acta Med. 2008; 51(2): 107–112

Foteinos-Ioannis, D.D, Anna G A, Anastasia E K, Nikolaos P, Fotini K, Fotios S, et al. Expression of Intracellular Components of the NF-κB Alternative Pathway (NF -κB2, RelB, NIK and Bcl3) is Associated with Clinical Outcome of NSCLC Patients. Sci Rep. 2019; 9: 14299.

Johnstone R W, Ruefli A A, Lowe S W. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108: 153–164.

Reed J C. Dysregulation of apoptosis in cancer. J Clin Oncol.1999; 17: 2941–2953.

Viatour P, Bentires-Alj M, Chariot A, Deregowski V, Leval L, Merville M-P, et al. NF-kB2/p100 induces Bcl-2 expression. Leukemia.2003;17, 1349–1356.

Stehlik C, de Martin R, Kumabashiri I, Schmid J A, Binder B R, Lipp J. Nuclear factor (NF)-kappaB-regulated X chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha induced apoptosis. J Exp Med. 1998; 188: 211–216.

Wang C Y, Mayo M W, Korneluk R G, Goeddel D V, Baldwin A S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c- IAP1 and c-IAP2 to suppress caspase 8 activation. Science.1998; 281: 1680–1683.

Krikos A, Laherty C D, Dixit V M. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappaB elements. J Biol Chem. 1992; 267: 17971–17976.

Jones P L, Ping D, Boss J.M. Tumor necrosis factor alpha and interleukin-1beta regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EBP-beta and NF-kappaB. Mol Cell Biol. 1997; 17: 6970–6981.

Dixon E P, Stephenson D T, Clemens J A, Little S P. Bcl-Xshort is elevated following severe global ischemia in rat brains. Brain Res.1997; 776: 222–229.

Chen F, Demers L M, Vallyathan V, Lu Y, Castranova V, Shi X. Involvement of 5’-flanking kappaB-like sites within bcl-x gene in silica-induced Bcl-x expression. J Biol Chem. 1999; 274: 35591–35595.

Grumont R J, Rourke I J, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation induced apoptosis. Genes Dev. 1999; 13: 400–411.

Tamatani M, Che Y H, Matsuzaki H, Ogawa S, Okado H, Miyake S, et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem. 1999; 274: 8531–8538.

Tsukahara T, Kannagi M, Ohashi T, Kato H, Arai M, Nunez G. et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol. 1999; 73: 7981–7987.

Wang CY, Guttridge DC, Mayo MW, Baldwin AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999; 19: 5923–5929.

Zong W X, Edelstein L C, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homologue Bfl-1/A1 is a direct transcriptional target of NFkappaB that blocks TNFalpha induced apoptosis. Genes Dev. 1999; 13: 382–387.

Bentires-Alj M, Dejardin E, Viatour P, Van Lint C, Froesch B, Reed J C, et al. Inhibition of the NF-kappaB transcription factor increases Bax expression in cancer cell lines. Oncogene. 2001; 20: 2805– 2813.

Sharmila G 1, Praba V. BCL2 expression in ductal carcinoma of breast and its association with other clinicopathologic variables. IP Arch Cytol Histopathol Res. 2020; 5(1): 75–80.

Nguyen C V, Nguyen Q T, Vu H T N, Phung H T, Pham K H, Le R D. Combined p53 and Bcl2 immunophenotypes in prognosis of vietnamese invasive breast carcinoma: A single institutional retrospective analysis, Technol Cancer Res Treat. 2020; 19: 1-12.

Kim T, Han W, Kim MK, Lee JW, Kim J, Ahn SK, et al. Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer. J Breast Cancer. 2015 Mar 1; 18(1): 16-21.

Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC, Agnantis NJ. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Anticancer Res. 2000 Nov 1; 20(6B): 4221-5.

Eom YH, Kim HS, Lee A, Song BJ, Chae BJ. BCL2 as a subtype-specific prognostic marker for breast cancer. J Breast Cancer. 2016 Sep 1; 19(3): 252-60.

Koo JY, Lee HD, Jung WH. Clinicopathological Correlation of Bcl-2 and p53 Immunohistochemistry in Breast Cancer. J Korean Cancer Assoc. 1997: 404-11.

Dejardin E, Bonizzi G, Bellahcene A, Castronovo V, Merville MP, Bours V. Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells. Oncogene. 1995 Nov 1; 11(9): 1835-41.